Evidence map›Paper›PMID 39552483›Full record

ArticleEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology2024

Feasibility of redo-TAVI in the self-expanding ACURATE neo2 valve: a computed tomography study.

Gintautas Bieliauskas, Yusuke Kobari, Arif A Khokhar, Mohamed Abdel-Wahab, Ahmed Abdelhafez, Miho Fukui, Klaus Fuglsang Kofoed, Dariusz Dudek, Andreas Fuchs, Joao Cavalcante and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Gintautas BieliauskasThe Heart Center, Rigshospitalet, Copenhagen, Denmark.
Yusuke KobariThe Heart Center, Rigshospitalet, Copenhagen, Denmark.
Arif A KhokharThe Heart Center, Rigshospitalet, Copenhagen, Denmark.
Mohamed Abdel-WahabHeart Center Leipzig, Leipzig, Germany.
Ahmed AbdelhafezHeart Center Leipzig, Leipzig, Germany.
Miho FukuiMinneapolis Heart Institute Foundation, Minneapolis, MN, USA.
Klaus Fuglsang KofoedThe Heart Center, Rigshospitalet, Copenhagen, Denmark.
Dariusz DudekJagiellonian University Medical College, Kraków, Poland.
Andreas FuchsThe Heart Center, Rigshospitalet, Copenhagen, Denmark.
Joao CavalcanteMinneapolis Heart Institute Foundation, Minneapolis, MN, USA.
Kentaro HayashidaDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan.
Gilbert H L TangDepartment of Cardiovascular Surgery, Mount Sinai Health System, New York, NY, USA.
Darren MylotteDepartment of Cardiology, Galway University Hospital, Galway, Ireland.
Vinayak N BapatMinneapolis Heart Institute Foundation, Minneapolis, MN, USA.
Ole De BackerThe Heart Center, Rigshospitalet, Copenhagen, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRedo-transcatheter aortic valve implantation (TAVI) may be unfeasible because of the risk of compromising coronary flow or coronary access by the pinned back leaflets of the index transcatheter aortic valve.

aimsWe aimed to evaluate the feasibility of redo-TAVI using the balloon-expandable SAPIEN 3 (S3) implanted within the self-expanding ACURATE neo2 (ACn2) valve and to identify predictors associated with a high risk of compromising coronary flow.

methodsA total of 153 post-ACn2 TAVI cardiac computed tomography scans were analysed. Redo-TAVI using an S3 was simulated in two positions: S3 outflow to the ACn2 upper crown (low implant) and S3 outflow to the base of the ACn2 commissural posts (high implant). The risk for coronary flow compromise and inaccessibility was determined by the height of the neoskirt created by the pinned back leaflets and the valve-to-aorta distances.

resultsAt a low S3 implant position, risk of coronary flow compromise was predicted in only 8% of patients and this increased to 60% with a high S3 position. In accordance, coronary access was predicted to be unrestricted in 52% versus 13% of patients with a low versus high S3 implantation. Female sex, a small aortic annular dimension and a sinotubular junction-to-aortic annulus mean diameter ratio <1.15 were independent predictors associated with a high risk for coronary flow compromise.

conclusionsThe feasibility of redo-TAVI with an S3 in an ACn2 depends on the implant depth of the S3 and the geometry of the surrounding aorta. A low S3 implant may reduce the risk of coronary flow compromise and inaccessibility.

Indexed as

Aortic ValveAortic Valve StenosisFeasibility StudiesHeart Valve ProsthesisTranscatheter Aortic Valve ReplacementAgedAged, 80 and overFemaleHumansMaleProsthesis DesignTomography, X-Ray ComputedTreatment Outcome

Identifiers

PMID39552483
PMCPMC11556403

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.